Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of intravitreal Zimura (avacincaptad pegol) for geographic atrophy in dry AMD
2015-003991-56Phase 2Completed
- Sponsor
- IVERIC bio
- Start
- Jan 2016
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of avacincaptad pegol in dry age-related macular degeneration and age-related macular degeneration (AMD) (2 arms), sponsored by IVERIC bio. Primary endpoints: Primary efficacy endpoint and Safety endpoints. Started Jan 2016; status: completed.
02
Drugs
avacincaptad pegol
03
Conditions
dry age-related macular degenerationage-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2015-003991-56.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003991-56.